Theratechnologies, Beaufour Ipsen Group deal

The companies agreed to develop TH-9506, TH.B's analog of pro-GRF (1-29) NH2 growth hormone-releasing factor, in cardiomyopathy and for patients who require maintenance dosage following prolonged trea...